Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience

Tatar B., Kose Ş., Ergun N. C., Turken M., Onlen Y., YILMAZ Y., ...Daha Fazla

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, cilt.65, sa.12, ss.1470-1475, 2019 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 65 Sayı: 12
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1590/1806-9282.65.12.1470
  • Dergi Adı: REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1470-1475
  • Anahtar Kelimeler: Hepatitis C, End-Stage Renal Disease, Sustained Virologic Response, SUSTAINED VIRAL RESPONSE, VIRUS GENOTYPES, INFECTION, INTERFERON, METAANALYSIS, EFFICACY, OMBITASVIR/PARITAPREVIR/RITONAVIR, COMBINATION, IMPAIRMENT, MANAGEMENT
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

OBJECTIVE: The recent development of direct-acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C, and interferon-based regimes have become a poor treatment choice in clinical practice. Today DAAs offer shorter, well-tolerated, highly effective curative therapies. This study aimed to evaluate the effectiveness and safety of DAAs in patients with end-stage renal disease and HCV genotype 1 infection in real clinical practice.